The pharmaceutical industry is undergoing a profound digital shift, driven not only by the pursuit of efficiency and innovation but also by regulatory imperatives from the European Union. Among these, the Digital Product Passport (DPP) is emerging as a game-changer—demanding a new level of traceability, transparency, and data integrity across the value chain. In this session, I will take you behind the curtain of international digitalization projects—drawing on lessons from end-users from different markets like discrete manufacturing, process and energy — and show how these insights can be applied in pharma to stay compliant, resilient, and competitive. This session will explore:

• OPC UA as the interoperability backbone: Why OPC UA has become the universal standard for secure, vendor-neutral, and scalable integration—bridging shop floor equipment, MES, cloud systems, and regulatory frameworks.
• EU Digital Product Passport readiness: How pharma companies can prepare for regulatory-driven traceability, ensuring compliance while unlocking new opportunities for digital twins, batch release optimization, and supply chain transparency.
• Scalable and secure data flow: From sensors to edge, from cloud to AI-driven digital twins, learn how to ensure compliance without compromising agility.

Digital transformation in pharma is no longer just about efficiency—it’s about meeting tomorrow’s regulations today. By embracing standardization, OPC UA interoperability, and EU-driven frameworks like the Digital Product Passport, pharma companies can build future-proof operations that are not only compliant but also more innovative, transparent, and competitive.